Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 20, 2019
The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.
Journal: Gynecologic oncology
Published: October 16, 2018
A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study.
Journal: Gynecologic oncology
Published: October 04, 2015
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Journal: Gynecologic oncology
Published: June 12, 2015
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 19, 2014
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
Journal: Gynecologic oncology
Published: September 27, 2012
Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response.
Journal: Journal of translational medicine
Published: January 18, 2012
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Journal: The New England journal of medicine
Published: December 30, 2011
A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer.
Journal: International journal of clinical oncology
Published: November 08, 2006
Showing 1-10 of 10
Last Updated: 09/26/2026